The global gene therapy market is projected to reach USD 36.55 billion by 2032 from USD 8.85 billion in 2024, at a CAGR of 19.4% during the forecast period of 2024 to 2032. The growth of the gene therapy market has been significantly driven by increasing R&D investment by key players for the development gene therapy drugs and growing approval of novel gene therapies. However, complex regulatory frameworks and ethical concerns regarding genetic modifications are restraining market growth.

“The intravenous route segment accounted for the largest share by route of administration in 2023.”
Based on route of administration, the gene therapy market is segmented into intravenous route, subcutaneous route and other routes. The intravenous route segment accounted for the largest share of the gene therapy market in 2023. The larger share of this segment is mainly attributed to the number of gene therapy administered through intravenous route is due to factors such as the high effectiveness of intravenous administration and high penetration of intravenous gene therapy currently approved and marketed products among others.

“The US has continued to dominate the gene therapy market during the forecast period of 2024-2032.”
The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from chronid disease, increasing biopharmaceuticals’ importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US).

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of key Companies Profiled in the Report:
Biogen Inc. (US), Novartis AG (Switzerland), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Jazz Pharmaceuticals Plc (Ireland), Ferring B.V. (Switzerland), Pfizer Inc. (US), Amgen, Inc. (US), Johnson & Johnson Services, Inc. (US), Daiichi Sankyo Company, Limited. (Japan), BioMarin Pharmaceutical Inc. (US), Kyowa Kirin Co., Ltd. (Japan), Nippon Shinyaku Co., Ltd. (Japan), PTC Therapeutics (US), UniQure NV (Netherlands), Juventas Cell Therapy Ltd. (China), CRISPR Therapeutics (Switzerland), bluebird bio, Inc. (US), Krystal Biotech, Inc. (US), Shanghai Sunway Biotech Co., Ltd. (China), JW (Cayman) Therapeutics Co. Ltd (China), IASO Biotechnology (China), CARsgen Therapeutics Holdings Limited (China), Adaptimmune (UK), Sibiono GeneTech Co. Ltd. (China), and Ultragenyx Pharmaceutical Inc. (US).

Research Coverage

This research report categorizes the gene therapy market by Therapy Type (Gene Silencing Therapy, Cell Replacement Therapy, Gene Augmentation Therapy and Other Therapies)), by Vector (Viral Vectors (Retroviral Vector (Gamma retroviral vectors, Lentiviral Vectors) AAV Vectors, and Other Viral Vectors), Non-viral Vectors (Oligonucleotides and Other Non-viral Vectors)), by Gene Type (Deficiency, Receptors, Antigen, Cytokine, Tumor Suppressor, and Othe Genes), by Therapeutic Area (Neurology, Oncology, Hematology and Other Therapeutic Areas), by Delivery Method (In Vivo and Ex Vivo), by Route of Administration (Intravenous Route, Subcutaneous Route, and Other Routes), by End User (Hospitals, Specialty Centers, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations and acquisitions, and recent developments associated with the gene therapy market.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (Growing demand for curative therapies for genetic disorders, rare diseases, and specific types of cancer, Increasing investments in gene therapy research, Growing technological advancements, and Robust clinical trial pipeline for gene therapy), restraints (High cost of gene therapy products, Complex regulatory frameworks and ethical concerns regarding genetic modifications, and Limited manufacturing scalability), opportunities (Expansion into rare diseases and unmet needs, Increasing focus on precision medicine, and Advancements in gene therapy delivery technologies), and Challenges (Complex manufacturing process, Short shelf life and supply chain challenges, and Lack of reimbursement).
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the gene therapy market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene therapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the gene therapy market.